Eleonora Mircia, Laurian Vlase, Gabriel Hancu, Monica Budău and Ruxandra Soare
criterion for dissolution profile interpretation. Drug Dev Ind Pharm. 2001;27:885-892.
 Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
Javor Mitkov, Nikolai Danchev, Irina Nikolova and Alexander Zlatkov
phenols, J. Am. Chem. Soc. 88 (1966) 1020--1024; DOI: 10.1021/ja00957a028.
D. L. Bowton, D. A. Stump, D. S. Prough, D. S. Lefkowitz and L. Coker, Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease, Stroke 20 (1989) 1662--1666.
C. D. Nicholson, Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia, Psychopharmacology 101 (1990) 147--159; DOI: 10.1007/BF02244119.
B. L. Eun, X. H. Liu and J. D. E. Barks
Amira A. Rashad, Sara Nageeb El-Helaly, Randa T. Abd El Rehim and Omaima N. El-Gazayerly
vitro characterization of a new nasal dosage form, Eur. J. Pharm. Sci . 27 (2006) 62–71; https://doi.org/10.1016/j.ejps.2005.08.005
23. M. S. Surapaneni, S. K. Das and N. G. Das, Effect of excipient and processing variables on adhesive properties and release profile of pentoxifylline from mucoadhesive tablets, Drug Dev. Ind. Pharm. 32 (2006) 377–387; https://doi.org/10.1080/03639040500519367
24. A. Tiraferri, P. Maroni, D. Caro Rodriguez and M. Borkovec, Mechanism of chitosan adsorption on silica from aqueous solutions, Langmuir 30 (2014
clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease, Hepatol. Int. 9 (2015) 471-479; DOI: 10.1007/s12072-015-9633-1.
43. T. Kopf, H. L. Schaefer, M. Troetzmueller, H. Koefeler, M. Broenstrup, T. Konovalova and G. Schmitz, Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats, PLOS ONE 9 (2014) e106849; DOI: 10.1371/journal.pone.0106849